These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

189 related items for PubMed ID: 14525705

  • 21. In vitro activities of garenoxacin (BMS-284756) against Haemophilus influenzae isolates with different fluoroquinolone susceptibilities.
    Pérez-Vázquez M, Román F, Aracil B, Cantón R, Campos J.
    Antimicrob Agents Chemother; 2003 Nov; 47(11):3539-41. PubMed ID: 14576114
    [Abstract] [Full Text] [Related]

  • 22. Comparative in-vitro activity of levofloxacin against isolates of bacteria from adult patients with community-acquired lower respiratory tract infections.
    Casellas JM, Gilardoni M, Tome G, Goldberg M, Ivanovic S, Orduna M, Dolmann A, Ascoli M, Ariza H, Montero JM.
    J Antimicrob Chemother; 1999 Jun; 43 Suppl C():37-42. PubMed ID: 10404336
    [Abstract] [Full Text] [Related]

  • 23. Comparison of the minimum inhibitory, mutant prevention and minimum bactericidal concentrations of ciprofloxacin, levofloxacin and garenoxacin against enteric Gram-negative urinary tract infection pathogens.
    Hansen GT, Blondeau JM.
    J Chemother; 2005 Oct; 17(5):484-92. PubMed ID: 16323436
    [Abstract] [Full Text] [Related]

  • 24. Comparison of the postantibiotic and postantibiotic sub-MIC effects of levofloxacin and ciprofloxacin on Staphylococcus aureus and Streptococcus pneumoniae.
    Licata L, Smith CE, Goldschmidt RM, Barrett JF, Frosco M.
    Antimicrob Agents Chemother; 1997 May; 41(5):950-5. PubMed ID: 9145850
    [Abstract] [Full Text] [Related]

  • 25. In vitro activity of fluoroquinolones against ocular bacterial isolates in São Paulo, Brazil.
    Oliveira AD, D'Azevedo PA, Francisco W.
    Cornea; 2007 Feb; 26(2):194-8. PubMed ID: 17251812
    [Abstract] [Full Text] [Related]

  • 26. Phenotypic resistance of Staphylococcus aureus, selected Enterobacteriaceae, and Pseudomonas aeruginosa after single and multiple in vitro exposures to ciprofloxacin, levofloxacin, and trovafloxacin.
    Gilbert DN, Kohlhepp SJ, Slama KA, Grunkemeier G, Lewis G, Dworkin RJ, Slaughter SE, Leggett JE.
    Antimicrob Agents Chemother; 2001 Mar; 45(3):883-92. PubMed ID: 11181375
    [Abstract] [Full Text] [Related]

  • 27. Comparative in vitro activity of three fluoroquinolones against clinical isolates by E test.
    Madhusudhan KT, Counts C, Lody C, Carter O, Dodson S, Ojha N.
    Chemotherapy; 2003 Jul; 49(4):184-8. PubMed ID: 12886053
    [Abstract] [Full Text] [Related]

  • 28. The comparative activity of fleroxacin, three other quinolones and eight unrelated antimicrobial agents.
    McCarter YS, Mazens-Sullivan MF, Bartlett RC.
    Chemotherapy; 1992 Jul; 38(5):308-18. PubMed ID: 1337507
    [Abstract] [Full Text] [Related]

  • 29. Anti-pneumococcal activity of gatifloxacin compared with other quinolone and non-quinolone agents.
    Hoellman DB, Lin G, Jacobs MR, Appelbaum PC.
    J Antimicrob Chemother; 1999 May; 43(5):645-9. PubMed ID: 10382885
    [Abstract] [Full Text] [Related]

  • 30. [In vitro activities of levofloxacin and other antibiotics against fresh clinical isolates].
    Matsuzaki K, Koyama H, Chiba A, Omika K, Harada S, Sato Y, Hasegawa M, Kobayashi I, Kaneko A, Sasaki J.
    Jpn J Antibiot; 1999 Sep; 52(9):571-84. PubMed ID: 10746192
    [Abstract] [Full Text] [Related]

  • 31. In vitro assessment of gatifloxacin spectrum and potency tested against Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae isolates from the Asia-Western Pacific component of the SENTRY antimicrobial surveillance program (1998-1999).
    Bell JM, Turnidge JD, Pfaller MA, Jones RN.
    Diagn Microbiol Infect Dis; 2002 Aug; 43(4):315-8. PubMed ID: 12151193
    [Abstract] [Full Text] [Related]

  • 32. Comparative in vitro activity of gemifloxacin, ciprofloxacin, levofloxacin and ofloxacin in a North American surveillance study.
    Hoban DJ, Bouchillon SK, Johnson JL, Zhanel GG, Butler DL, Miller LA, Poupard JA, Gemifloxacin Surveillance Study Research Group.
    Diagn Microbiol Infect Dis; 2001 Aug; 40(1-2):51-7. PubMed ID: 11448564
    [Abstract] [Full Text] [Related]

  • 33. [Resistance profiles to fluoroquinolones in clinical isolates of Gram positive cocci].
    Hidalgo M, Reyes J, Cárdenas AM, Díaz L, Rincón S, Vanegas N, Díaz PL, Castañeda E, Arias CA.
    Biomedica; 2008 Jun; 28(2):284-94. PubMed ID: 18719726
    [Abstract] [Full Text] [Related]

  • 34. In vitro susceptibility of 4903 bacterial isolates to gemifloxacin--an advanced fluoroquinolone.
    Blondeau JM, Hansen G, Metzler KL, Borsos S, Irvine LB, Blanco L.
    Int J Antimicrob Agents; 2003 Aug; 22(2):147-54. PubMed ID: 12927955
    [Abstract] [Full Text] [Related]

  • 35. Pharmacodynamic assessment of the activity of high-dose (750 mg) levofloxacin, ciprofloxacin, and gatifloxacin against clinical strains of Pseudomonas aeruginosa.
    Garrison MW.
    Diagn Microbiol Infect Dis; 2006 Jan; 54(1):51-6. PubMed ID: 16368475
    [Abstract] [Full Text] [Related]

  • 36. [Activities of antimicrobial agents against 5,180 clinical isolates obtained from 26 medical institutions during 1998 in Japan. Levofloxacin--Surveillance Group].
    Yamaguchi K, Miyazaki S, Kashitani F, Iwata M, Kanda M, Tsujio Y, Okada J, Tazawa Y, Watanabe N, Uehara N, Igari J, Oguri T, Kaimori M, Kawamura C, Iinuma Y, Nisawataira T, Tashiro H, Ueno K, Ishigo S, Yasujima M, Kawahara S, Itoh C, Yoshida T, Yamanaka K, Toyoshima S, Katoh J, Kudoh M, Matsushima T, Niki Y, Miyashita N, Funato T, Kaku M, Sato N, Saito Y, Ishii K, Kuwabara M, Hongo T, Negayama K, Kamihira S, Miyazaki Y, Takii M, Ishii M, Nakagawa K, Ono J, Takada T, Murakami N, Taira M, Tamaki I, Matsudou Y, Nakasone I.
    Jpn J Antibiot; 2000 Jun; 53(6):387-408. PubMed ID: 10955236
    [Abstract] [Full Text] [Related]

  • 37. Susceptibility of European respiratory tract isolates to trovafloxacin, ciprofloxacin, clarithromycin, azithromycin and ampicillin.
    Pontani D, Washton H, Bouchillon S, Johnson J.
    Eur J Clin Microbiol Infect Dis; 1998 Jun; 17(6):413-9. PubMed ID: 9758284
    [Abstract] [Full Text] [Related]

  • 38. Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin.
    Bauernfeind A.
    J Antimicrob Chemother; 1997 Nov; 40(5):639-51. PubMed ID: 9421311
    [Abstract] [Full Text] [Related]

  • 39. In-vitro bacteriostatic activity of levofloxacin and three other fluoroquinolones against penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae.
    Frémaux A, Sissia G, Geslin P.
    J Antimicrob Chemother; 1999 Jun; 43 Suppl C():9-14. PubMed ID: 10404331
    [Abstract] [Full Text] [Related]

  • 40. Comparative activity of quinolones (ciprofloxacin, levofloxacin, moxifloxacin and garenoxacin) against extracellular and intracellular infection by Listeria monocytogenes and Staphylococcus aureus in J774 macrophages.
    Seral C, Barcia-Macay M, Mingeot-Leclercq MP, Tulkens PM, Van Bambeke F.
    J Antimicrob Chemother; 2005 Apr; 55(4):511-7. PubMed ID: 15731197
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.